Early Clinical Development / Phase IIa
An experienced partner gets you results as you introduce your compound in humans and move to proof of concept.
“Go / No-Go” Decisions Earlier with the Right Partner.
Your clinical pharmacology team brings over 30 years of direct drug development experience
Your partners include over 250 staff fully dedicated to early patient studies
Optimize your early patient studies with over 300 investigator sites around the globe
Early clinical missteps hold you back — we don’t let them happen.
Study delays and missed recruitment timelines are far too common. Your main considerations are quality, time and cost. By partnering with Covance, you can rest assured that your drug will stay on track toward the next development milestone. Our processes are specifically designed for early clinical studies. In fact, we have locked over 1,000 databases and met our healthy volunteer and patient enrollments over 90% in the past 5 years.
Keeping it simple in an increasingly complicated landscape.
You only need access to the resources that matter most to your study and you shouldn’t have to deal with a bigger footprint than you need. We understand. That’s why we deliver the right combination of strategy and execution, resources and tools that help you meet your end goals.
Deep therapeutic experience matters in clinical design.
You want a team of experts that have a proven track record in your therapeutic area. We deliver recognized thought leaders in early clinical design and execution for a variety of therapeutic indications including oncology, metabolic, neuroscience, cardiovascular, inflammation and infectious disease.
An experienced partner to help you navigate your first-in-human studies.
We offer you a deep, experienced team focused on this crucial phase of molecule development. Let us partner with you as you transition into the clinic with an eye toward future phases.